Anti-Human PD-L1 (CD274) (Clone 29E.2A3) - APC

Leinco Technologies
Product Code: LEI-P609
Product Group: Primary Antibodies
CodeSizePrice
LEI-P609-25ug25 ug£167.00
Quantity:
LEI-P609-100ug100 ug£283.00
Quantity:
LEI-P609-500ug500 ug£862.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: Mouse IgG2b κ
Antibody Clonality: Monoclonal
Antibody Clone: 29E.2A3
Regulatory Status: RUO
Target Species: Human
Application: Functional Study
Shipping:
2 - 8°C Wet Ice
Storage:
This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze.

Further Information

Antigen Distribution:
PD-L1 is commonly expressed on the surface of antigen presenting cells (macrophages, activated B cells, dendritic cells), some epithelial cells under inflammatory conditions, some activated T cells, and several types of tumors as well as tumor infiltrating immune cells. PD-L1 can also exist in a soluble form (sPD-L1) in myeloid-derived cells (monocytes, macrophages, and dendritic cells) and several human cancer lines.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
Allophycocyanin (APC)
Format:
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Full length Human PD-L1
Long Description:
Programmed cell death 1 ligand 1 (PD-L1; CD274; B7-H1) is a type I transmembrane glycoprotein widely expressed in many types of tissues that acts as a ligand for the immune inhibitory receptor programmed cell death 1 (PD-1; CD279)1, 2, 3. The PD-1 pathway is responsible for T cell activation, proliferation, and cytotoxic secretion, with PD-1/PD-L1 interaction triggering inhibitory signals that dampen T cell function. PD-L1 also plays a critical role in the differentiation of inducible regulatory T cells4. In normal tissues, PD-L1/PD-1 ligation is crucial to maintaining homeostasis of the immune system and preventing autoimmunity during infection and inflammation4. In the tumor microenvironment, their interaction provides an immune escape mechanism for tumor cells by turning off cytotoxic T cells. As such, blocking the PD-L1/PD-1 interaction is a target of many anti-cancer immunotherapies. 29E.2A3 was generated by immunizing female BALB/c mice with purified hPD-L1 cDNA5. Spleen cells were fused with SP2/0 myeloma cells, and the resulting hybridomas were screened by ELISA for reactivity against hPD-L1?Ig fusion protein followed by cell-surface staining of hPD-L1?transfected Chinese hamster ovary cells and 300.19 cells.
NCBI Gene:
29126
Target:
PD-L1

References

1. Freeman GJ, Long AJ, Iwai Y, et al. J Exp Med. 2000192(7):1027-1034. 2000. 2. Tsai KK, Zarzoso I, Daud AI. Hum Vaccin Immunother. 10(11):3111-3116. 2014. 3. Han Y, Liu D, Li L. Am J Cancer Res. 10(3):727-742. 2020. 4. Dermani FK, Samadi P, Rahmani G, et al. J Cell Physiol. 234(2):1313-1325. 2019. 5. Latchman Y, Wood CR, Chernova T, et al. Nat Immunol. 2(3):261-268. 2001. 6. Brown JA, Dorfman DM, Ma FR, et al. J Immunol. 170(3):1257-1266. 2003. 7. Cai G, Karni A, Oliveira EM, et al. Cell Immunol. 230(2):89-98. 2004. 8. Porichis F, Hart MG, Zupkosky J, et al. J Virol. 88(5):2508-2518. 2014. 9. Hughes MJ, McGettrick HM, Sapey E. J Immunol Methods. 483:112795. 2020. 10. Boyerinas B, Jochems C, Fantini M, et al. Cancer Immunol Res. 3(10):1148-1157. 2015. 11. Nakamoto N, Cho H, Shaked A, et al. PLoS Pathog. 5(2):e1000313. 2009. 12. Hegde S, Lockridge JL, Becker YA, et al. J Autoimmun. 37(1):28-38. 2011. 13. Broos K, Lecocq Q, Keersmaecker B, et al. Vaccines (Basel). 7(3):85. 2019. 14. Darga EP, Dolce EM, Fang F, et al. PLoS One. 16(11):e0260124. 2021.